Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair

BACKGROUND: We evaluated the impact of 3 months of mFOLFOX6 adjuvant chemotherapy or surgery alone in comparison with 6 months of mFOLFOX6 on disease-free survival (DFS) in deficient mismatch repair (dMMR) colon cancer (CC) patients. METHODS: This retrospective study identified a cohort of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Huabin, Wu, Zehua, Wang, Chao, Huang, Yan, Zhang, Jianwei, Cai, Yue, Xie, Xiaoyu, Li, Jianxia, Shen, Cailu, Li, Weiwei, Ling, Jiayu, Xu, Xuehu, Deng, Yanhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747753/
https://www.ncbi.nlm.nih.gov/pubmed/33344234
http://dx.doi.org/10.3389/fonc.2020.579478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747753/
https://www.ncbi.nlm.nih.gov/pubmed/33344234
http://dx.doi.org/10.3389/fonc.2020.579478

Ejemplares similares